Relative effects of angiotensin converting enzyme inhibitors and calcium antagonists in advanced diabetic nephropathy

Ethnicity and Disease

Volumn 14, Issue 1, 2004, Pages 87-93

  Crook, Errol D ^a,b   Preddie, Dean C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

African American; Angiotensin converting enzyme inhibitor; Calcium channel blocker; Diabetic nephropathy; Hypertension; Renal survival

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREVALENCE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL;

ACADEMIC MEDICAL CENTERS; ADULT; AFRICAN AMERICANS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; CREATININE; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MEDICAL RECORDS; MIDDLE AGED; MISSISSIPPI; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 1342309264     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. US Renal Data System. USRDS 1999 Annual Data Report. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
2. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
3. Lewis EJ. Captopril in Type 1 Diabetic Nephropathy. In: Black HR, ed. Clinical Trials in Hypertension. New York, NY: Marcel Dekker, Inc; 2001:451-468.
4. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces the rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1: 1175-1179.
5. Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus: a 14-year follow-up report on 195 patients. Arch Intern Med. 1992;152:1225-1229.
6. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456-1462.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861-869.
8. Lewis EJ, Lawrence HG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
9. Wright JT Jr, Bakris G, Greene T, et al, for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA. 2002;288:2421-2431.
10. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
11. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
12. Hall WD, Reed JW, Flack JM, et al. Comparison of the efficacy of dihydropyridine calcium channel blockers in African-American patients with hypertension. International Society of Hypertension in Blacks Investigator Group. Arch Intern Med. 1998;158:2029-2034.
13. Crook ED, Harris J, Oliver B, Fleischman E, Crenshaw G, Taylor R. Endstage renal disease due to diabetic nephropathy in Mississippi: an examination of factors influencing renal survival in a population prone to late referral. J Invest Med. 2001;49:284-291.
14. Crook ED, Wofford P, Oliver B. Advanced diabetic nephropathy disproportionately affects African-American females: cross-sectional analysis and determinants of renal survival in an academic renal clinic. Ethn Dis. 2003; 13:28-33.
15. Bakris GL, Weir MR, Dequattro V, McMahon FG. Effects of ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54: 1283-1289.
16. Bakris GL, Griffin KA, Picken MM, Bidani AK. Combined effects of angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997;15: 1181-1185.
17. Crook ED. Diabetic Renal Disease in African Americans. Am J Med Sci. 2002;323:78-84.
18. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
19. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340: 677-684.
20. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensives therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
22. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685-693.
23. Anonymous. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-2446.
24. Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525-541.
25. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419.
26. Crook ED, Thallapureddy A, Migdal S, et al. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease. Am J Med Sci. 2003;325:340-348.